en English
ar Arabiczh-CN Chinese (Simplified)nl Dutchen Englishfr Frenchde Germanit Italianpt Portugueseru Russianes Spanish

FL is the second most common type of non-Hodgkin lymphoma(NHL), accounting for ~ 20% of all lymphomas.1

Icon Icon

What is Follicular
Lymphoma (FL)?

Follicular Lymphoma (FL) is a type of non-Hodgkin indolent lymphoma that affects the cells of the immune system.2

B cells, T cells and glands called lymph nodes make up the body’s immune system which protects the body from diseases.3 Sometimes, the cells inside a lymph node can grow abnormally and become cancerous. Patients with Follicular Lymphoma cancer have abnormal (cancerous) B cells that develop in clumps called ‘follicles’ inside the lymph nodes, and potentially other parts of the body. Follicular lymphoma cancer symptoms include swollen lymph nodes in neck, armpit, abdomen, or groin.2

What is Pediatric Acute Lymphoblastic Leukemia (pALL)?
What is Pediatric Acute Lymphoblastic Leukemia (pALL)?

What are Follicular Lymphoma
(FL) treatment options?

In cancer care, the treatment options3 and recommendations depend on several factors, including the type of lymphoma, the stage (extent) of your disease, age and overall health. As treatment plans for Follicular Lymphoma (FL) cancer vary from patient to patient, it is essential to discuss your unique case history and symptoms with your care team.
CHEMOTHERAPY

CHEMOTHERAPY

Chemotherapy often consists of a combination of several medications which help to stop the spread of fast-growing cancer cells.4

TARGETED THERAPY

TARGETED THERAPY

A type of treatment where specific parts of the cancer cells is identified and blocked to prevent them from spreading.5 It is often used alone or in combination with other therapies, such as chemotherapy or radiation therapy.

IMMUNOTHERAPY

IMMUNOTHERAPY

Patient’s immune system is enhanced using medicines to better recognize and treat cancer cells.6 Examples include immune checkpoint inhibitors, immune system modulators, monoclonal antibodies, and T-cell therapy.

CHIMERIC ANTIGEN RECEPTOR (CAR) T-CELL THERAPY

CAR-T cell therapy is a type of immunotherapy used to treat cancer with altered immune cells. These specially altered white blood cells, called T cells, are modified to find and stop the spread of cancer cells in the body.9

RADIATION THERAPY

RADIATION THERAPY

High-energy radiation is used to treat cancer cells. It is an important step before a bone marrow or stem cell transplant.7

STEM CELL TRANSPLANT

STEM CELL TRANSPLANT

Impaired or diseased bone marrow is replaced with healthy cells from the patient’s own bone marrow or form a suitable donor.8

Learn more

What is CAR-T cell therapy?

Learn more about CAR-T cell therapy, an innovative form of immunotherapy for ALL, DLBCL and FL patients whose current treatment may not be responding, or whose cancer has relapsed.9, 10

CAR-T therapy involves altering your body’s own T cells, a type of white blood cell found in the immune system, with new chimeric antigen receptors (or CAR for short). When the CAR is combined with your T cells, the CAR-T cell therapy enhances the body’s natural ability to treat cancer with reprogrammed T cells.9 Thus, having the potential to cure the cancer completely with a one-time treatment. Click on the video to learn more.

DID YOU KNOW

10,000+ patients worldwide have already experienced CAR-T cell
therapy treatment

since the first FDA approved therapy was made available in 2017.11,12

Learn More

When to consider CAR-T?

CAR-T cell therapy is an individualized treatment made from the body’s own T cells. However, data shows that T cell health will decline over time and result in poorer outcomes especially when additional therapies such as chemotherapy have been performed.13

<strong>Potentially curative treatment for<br/> patients who are not responding well<br/> to initial treatments</strong>

Potentially curative treatment for
patients who are not responding well
to initial treatments

<strong>Harnesses the power of your own<br/> T cells to detect and treat<br/> cancerous B cells</strong>

Harnesses the power of your own
T cells to detect and treat
cancerous B cells

<strong>A one-time infusion treatment<br/> either with or without<br/> hospitalization</strong>

A one-time infusion treatment
either with or without
hospitalization

Learn More
Is CAR-T right for<br/> your loved one?

Is CAR-T right for
your loved one?

CAR-T cell therapy is a one-time, potentially curative, and innovative treatment option. It is approved worldwide (by the FDA since 20177 and over 30 other health authorities) for patients who have certain types of leukemia and lymphoma, including Pediatric Acute Lymphoblastic Leukemia (pALL), Diffuse Large B-cell Lymphoma (DLBCL), as well as Follicular Lymphoma (FL) in 2022.9, 10

CAR-T MAY BE A SUITABLE OPTION FOR PATIENTS WHOSE CANCER:

  • Has relapsed after 2 or more prior lines of systemic therapy (went into recovery, then came back)
  • Is refractory (became resistant and non-responsive to standard Follicular Lymphoma treatment)

While the goal of CAR-T cell therapy is long-term recovery of cancer, it is important to note that not all patients will respond the same way to Follicular Lymphoma treatment.

  • ~20% of patients relapsed 15
  • ~15-25% of patients are diagnosed with Stage I-II FL16
  • ~70%-80% of patients are diagnosed with Stage III or IV FL17
Find support here
Is CAR-T right for<br/> your loved one?
Hear the stories of Pediatric Acute Lymphoblastic Leukemia (pALL) patients and caregivers

Discover patients and caregiver experiences with
CAR-T and Follicular Lymphoma (FL)

Hear the stories of Pediatric Acute Lymphoblastic Leukemia (pALL) patients and caregivers Learn More

References

  1. (2021). Lymphoma – Non-Hodgkin: Subtypes. Cancer.Net. https://www.cancer.net/cancer-types/lymphoma-non-hodgkin/subtypes

  2. Lymphoma Action. Follicular lymphoma. Lymphoma Action. (2022). Retrieved October 11, 2022, from https://lymphoma-action.org.uk/types-lymphoma-non-hodgkin-lymphoma/follicular-lymphoma

  3. Treating B-cell non-Hodgkin lymphoma. (n.d.). Cancer.Org. Retrieved October 11, 2022, from https://www.cancer.org/cancer/non-hodgkin-lymphoma/treating/b-cell-lymphoma.html

  4. Chemotherapy for acute Lymphocytic leukemia (ALL). (n.d.). Cancer.Org. Retrieved March 11, 2022, from https://www.cancer.org/cancer/acute-lymphocytic-leukemia/treating/chemotherapy.html

  5. Targeted therapy for acute Lymphocytic leukemia (ALL). (n.d.). Cancer.Org. Retrieved October 11, 2022, from https://www.cancer.org/cancer/acute-lymphocytic-leukemia/treating/targeted-therapy.html

  6. Immunotherapy for acute Lymphocytic leukemia (ALL). (n.d.). Cancer.Org. Retrieved October 11, 2022, from https://www.cancer.org/cancer/acute-lymphocytic-leukemia/treating/monoclonal-antibodies.html

  7. Radiation therapy for childhoodleukemia.(n.d.).Cancer.Org.RetrievedMarch11,2022,from: https://www.cancer.org/cancer/leukemia-in-children/ treating/radiation.html

  8. Stem Cell Transplant: Pioneering cancer therapy. (n.d.). Novartis. Retrieved October 21, 2022, from https://www.novartis.com/research-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-cell-therapy-pioneering-cancer-therapy

  9. CAR-T cell therapy: Pioneering cancer therapy. (n.d.). Novartis. Retrieved October 21, 2022, from https://www.novartis.com/research-development/technology-platforms/cell-therapy/car-t-cell-therapy-and-beyond/car-t-cell-therapy-pioneering-cancer-therapy

  10. FDA approves Novartis Kymriah® Car-T cell therapy for adult patients with relapsed or refractory follicular lymphoma. Novartis. (2022, May 28). Retrieved October 20, 2022, from https://www.novartis.com/news/media-releases/fda-approves-novartis-kymriah-car-t-cell-therapy-adult-patients-relapsed-or-refractory-follicular-lymphoma

  11. Pharma,K.(2021).Yescarta Patient Brochure – extracted from Novartis resource

  12. Novartis. (n.d.). Kymriah Patient Numbers – extracted from Novartis resource

  13. Novartis. (2021). Kymriah Real-World Evidence Summary – extracted from Novartis resource

  14. Kymriah® (tisagenlecleucel), first-in-class CAR-T therapy from Novartis, receives second FDA approval to treat appropriate r/r patients with large B-cell lymphoma. (n.d.). Novartis. Retrieved March 11, 2022, from https://www.novartis.com/news/media-releases/kymriah-tisagenlecleucel-first-class-car-t-therapy-from-novartis-receives-second-fda-approval-treat-appropriate-rr-patients-large-b-cell-lymphoma

  15. Helwick, C. (2016). Early Relapse in Follicular Lymphoma: Clinical Trial Data May Guide Management Decisions. The ASCO Post. https://ascopost.com/issues/september-10-2016/early-relapse-in-follicular-lymphoma-clinical-trial-data-may-guide-management-decisions/

  16. Surveillance, Epidemiology, and End Results (SEER) Program. Cancer Stat Facts: NHL – Follicular Lymphoma. Bethesda, MD: National Cancer Institute (NCI); April 2021:1-8.

  17. Novartis. (2022). Kymriah FL Disease State Training. – extracted from Novartis resource